Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4367-0.0411 (-8.60%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.4778
Open0.4797
Bid0.4401 x 1000
Ask0.4498 x 1300
Day's Range0.4333 - 0.4797
52 Week Range0.3800 - 1.1200
Volume189,408
Avg. Volume164,977
Market Cap18.824M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.3490
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Soligenix, Inc.
    Analyst Report: Emergent BioSolutions IncEmergent BioSolutions makes vaccines and other products intended to protect civilian and military populations from emerging infectious diseases and chemical, biological or nuclear attacks. The company generates its revenue from product sales of its smallpox vaccine (ACAM2000), its anthrax vaccines (BioThrax and AV7909), and its Narcan nasal spray (a treatment for opioid overdoses), as well as from contract development and manufacturing services and contracts and grants. The USG is the company's primary customer, and provides EBS with significant product development funding. EBS shares are a component of the S&P 400 Index. The company has approximately 2,400 employees.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • PR Newswire

    Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 22, 2022 has been partially adjourned for the purpose of soliciting additional votes with respect to Proposal 2, the approval of an amendment to the Company's Second

  • Newsfile

    FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL

    New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryte™ therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), ...

  • PR Newswire

    Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The conference will be held September 12 through 14, 2022 with presentations, one-on-one meetings, and networking. The on-demand presentation wil

Advertisement
Advertisement